Prognostic value of circulating mitochondrial DNA in prostate cancer and underlying mechanism

Circulating DNAs are considered as degraded DNA fragments of approximately 50-200 bp, found in blood plasma, consisting of cell-free mitochondrial and nuclear DNA. Such cell-free DNAs in the blood are found to be altered in different pathological conditions including lupus, heart disease, and malignancies. While nuclear DNAs are being used and being developed as a powerful clinical biomarker in liquid biopsies, mitochondrial DNAs (mtDNAs) are associated with inflammatory conditions including cancer progression. Patients with cancer including prostate cancer are found to have measurable concentrations of mitochondrial DNA in circulation in comparison with healthy controls. The plasma content of mitochondrial DNA is dramatically elevated in both prostate cancer patients and mouse models treated with the chemotherapeutic drug. Cell-free mtDNA, in its oxidized form, induced a pro-inflammatory condition and activates NLRP3-mediated inflammasome formation which causes IL-1 & beta;-mediated activation of growth factors. On the other hand, interacting with TLR9, mtDNAs trigger NF-& kappa;B-mediated complement C3a positive feedback paracrine loop and activate pro-proliferating signaling through upregulating AKT, ERK, and Bcl2 in the prostate tumor microenvironment. In this review, we discuss the growing evidence supporting cell-free mitochondrial DNA copy number, size, and mutations in mtDNA genes as potential prognostic biomarkers in different cancers and targetable prostate cancer therapeutic candidates impacting stromal-epithelial interactions essential for chemotherapy response.

Automated summary

Circulating DNAs are fragmented DNA in blood plasma, including cell-free mitochondrial and nuclear DNA, and are altered in various pathological conditions. Mitochondrial DNA is associated with inflammation and elevated in cancer patients. It induces pro-inflammatory conditions and activates growth factors. It also triggers a positive feedback loop and activates pro-proliferating signaling in the tumor microenvironment. This review discusses the potential prognostic biomarkers and therapeutic candidates in different cancers, particularly prostate cancer.